Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
